Clinical Context
When semaglutide was in development, the established GLP-1 RA benchmark was liraglutide—a daily injectable with proven efficacy for both type 2 diabetes (Victoza) and obesity (Saxenda). Understanding how semaglutide compared to liraglutide was essential for determining its place in the therapeutic landscape. Would the newer agent offer meaningful improvements, or simply be another “me too” option?
This Phase 2 dose-finding study systematically compared multiple semaglutide doses against multiple liraglutide doses in patients with type 2 diabetes. By including dose-ranging for both compounds, the trial could assess not just whether semaglutide was better, but whether equivalence could be achieved at lower doses—with potential implications for tolerability.
The study population represented a common clinical scenario: patients with type 2 diabetes on diet and exercise with or without metformin who needed treatment intensification. These patients are early in their treatment journey and represent an important target for GLP-1 RA therapy.
PICO Summary
Population: Adults with type 2 diabetes (n=705), HbA1c 7.0-10.0%, managed with diet and exercise alone or with metformin.
Intervention: Once-daily subcutaneous semaglutide at various doses (0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg) for 26 weeks.
Comparison: Once-daily liraglutide at various doses (0.3 mg, 0.6 mg, 0.9 mg, 1.2 mg, 1.8 mg) and placebo.
Outcome: Semaglutide demonstrated dose-dependent HbA1c reductions up to 1.8% (at 0.3 mg), exceeding liraglutide’s maximum 1.4% reduction (at 1.8 mg). Weight loss followed similar patterns: up to 5.7 kg with semaglutide 0.3 mg versus 3.0 kg with liraglutide 1.8 mg. Gastrointestinal adverse events were more frequent with semaglutide, particularly at higher doses.
Clinical Pearls
1. Semaglutide Achieves Greater Efficacy at Lower Doses: Semaglutide 0.1 mg daily produced comparable HbA1c reduction to liraglutide 1.2 mg daily, while semaglutide 0.2 mg exceeded even liraglutide 1.8 mg (the maximum approved dose). This potency advantage allows therapeutic effects with less total drug exposure.
2. Superior Weight Loss Adds Clinical Value: The 5.7 kg weight loss with semaglutide 0.3 mg versus 3.0 kg with liraglutide 1.8 mg represents nearly double the weight effect. For patients with type 2 diabetes and obesity—the majority of this population—enhanced weight loss is clinically meaningful.
3. GI Effects Are Dose-Related: Higher semaglutide doses produced more gastrointestinal side effects (nausea, vomiting, diarrhea). This established the importance of gradual dose titration and informed the development of standardized escalation protocols for clinical use.
4. Phase 2 Data Informed Weekly Formulation: While this study used daily dosing, the pharmacokinetic and dose-response data informed development of the once-weekly formulation that ultimately reached market. The superior potency of semaglutide enabled weekly dosing with sustained therapeutic effects.
Practical Application
This study established semaglutide’s superiority over liraglutide for both glycemic control and weight loss in type 2 diabetes. For patients previously on liraglutide with suboptimal response, transitioning to semaglutide offers potential for greater efficacy. The weekly formulation (Ozempic) that reached market provides additional convenience advantages.
When initiating semaglutide, the dose-response data from this trial support starting low and titrating gradually. The standard protocol (0.25 mg weekly for 4 weeks → 0.5 mg weekly for 4 weeks → 1.0 mg weekly, with option to increase to 2.0 mg) allows the GI tract to adapt and minimizes early discontinuation due to side effects.
For patients experiencing inadequate response at 0.5 mg or 1.0 mg weekly, increasing to higher doses can be expected to produce additional HbA1c and weight reduction based on the clear dose-response relationship demonstrated in this trial.
Broader Evidence Context
This Phase 2 trial preceded the comprehensive SUSTAIN program that established semaglutide across the type 2 diabetes treatment spectrum. SUSTAIN 10 subsequently provided a Phase 3 head-to-head comparison confirming semaglutide 1.0 mg weekly’s superiority over liraglutide 1.2 mg daily in real-world-like conditions.
The potency advantage demonstrated in this trial translated to both diabetes (Ozempic) and obesity (Wegovy) indications, establishing semaglutide as the most effective GLP-1 RA available until the emergence of dual GIP/GLP-1 agonists (tirzepatide).
Study Limitations
The 26-week duration is relatively short for assessing durability and long-term safety. Daily dosing differs from the weekly formulation ultimately marketed. The multiple dose arms resulted in relatively small numbers per group. Long-term cardiovascular outcomes weren’t assessed.
Bottom Line
Daily semaglutide produces superior glycemic control and weight loss compared to daily liraglutide at comparable or lower doses in patients with type 2 diabetes. This Phase 2 trial established semaglutide’s potency advantage over the previous GLP-1 RA benchmark and informed development of the once-weekly formulation now widely used in clinical practice.
Source: Lingvay I, et al. “A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients with Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.” Diabetes Care, 2018;41(9):1926-1937. Read article